Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYRAMID: R-CHOP +/- Bortezomib in Non-GCB DLBCL
NCT00931918Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2009
- Primary completion
- Aug 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Millennium Pharmaceuticals. Primary endpoints: Progression-Free Survival at 34.4 months and Progression-Free Survival Rate at 2 years. Started Oct 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00931918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931918.